Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Export from Russia in 2019

Monday, March 16, 2020

In 2019, Russia exported 46 bln RUB worth of pharmaceutical drugs (customs duties included), which is in monetary terms (rubles) 13% higher than that in 2018. The export volume in physical terms amounted to more than 0.95 bln units, with the dynamics of +17.9%.

The EEU countries (Belarus, Kazakhstan, Kyrgyzstan and Armenia) account for 37.1% of the total export in monetary terms (against 35.7% in 2018 and 40.1% in 2016), or 17.1 bln RUB.

In 2019, Russia exported to 109 different countries. The top 10 countries (post-Soviet republics and Nigeria) account for 80% of the export in monetary terms. Nigeria accounts for 4% of the export; in 2019, Russia exported only Yellow Fever Vaccine by Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of Russian Academy of Sciences. Among the 7 new export directions, Iran, working with Biocad, accounts for the highest export volume.

Ukraine remains the leader in export volume, accounting for 16.7% of the export in monetary terms (7.7 bln RUB). However, Donetsk People’s Republic and Luhank People’s Republic, where Russia mainly exports mass demand drugs of non-Russian origin, produced by more than 460 companies (Sanofi, TEVA, Novartis and Takeda among the largest), account for more than 96% of the export. Only a few Russian companies exported there, Stada (Hexicon, Livarol and others) and Mir Pharm (Phenybut) among them.

Lithuania (exports have grown by 57%) and Turkmenistan (41%) have the highest dynamics among the top 10 recipient countries. Biocad (Herticad, Bevacizumab and Genferon) and Geropharm (Cortexin and Retinalamin) actively exported to Lithuania, and Syntez exported a large number of antibacterials to Turkmenistan.

Exports to Uganda have grown by record-worthy 1000 times; in 2019, Russia exported 5.2 bln RUB worth of Yellow Fever Vaccine, Bevacuzumab, and Trastuzumab.

Dynamics of pharmaceutical drug export from Russia (including to the EEU countries), 2015 – 2019, customs duties included